CX Institutional’s CRISPR Therapeutics CRSP Stock Holding History

CX Institutional’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9K	Hold	174	–	–	﹤0.01%	1307
2026 Q1	$8K	Hold	174	–	–	﹤0.01%	1321
2025 Q4	$9K	Hold	174	–	–	﹤0.01%	1203
2025 Q3	$11K	Buy	174 +10	+6%	+$574	﹤0.01%	1179
2025 Q2	$8K	Hold	164	–	–	﹤0.01%	1063
2025 Q1	$6K	Buy	+164	New	+$6.95K	﹤0.01%	1049
2022 Q3	–	Sell	-10	Closed	-$1K	–	597
2022 Q2	$1K	Buy	+10	New	+$588	﹤0.01%	1126

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

LIM

Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

CX Institutional's CRSP Position: Q2 2026 in Review

CX Institutional held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 174 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1307.

CX Institutional first reported a position in CRSP in Q2 2022 and has held it in 7 quarters since. The position peaked at $11K in Q3 2025. 71 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

CX Institutional held 174 shares of CRISPR Therapeutics worth $9K as of Q2 2026.
CX Institutional left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1307 holding.
CX Institutional first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 7 quarters since.
CX Institutional's CRISPR Therapeutics position peaked at $11K in Q3 2025.
71 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.